Jefferies analyst Dennis Ding has maintained their bullish stance on NAMS stock, giving a Buy rating today.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Dennis Ding has given his Buy rating due to a combination of factors that highlight the potential of NewAmsterdam Pharma Company. One of the key reasons is the company’s commitment to achieving a broader FDA label through the MACE-4 endpoint for their PREVAIL study, which is expected to deliver significant cardiovascular benefits. Ding dismisses investor concerns about stroke impacts, emphasizing that the data from the BROADWAY analysis supports a positive outlook, particularly with contributions from small LDL-P and Lp(a) that align with expectations.
Additionally, Ding notes that the potential MACE benefit from PREVAIL could exceed 20%, which is a promising indicator for the company’s future performance. He also highlights the unique position of obicetrapib in the market, suggesting it could drive substantial benefits. Furthermore, Ding points out the Alzheimer’s aspect as an additional opportunity, enhancing the attractiveness of the stock. Overall, these factors contribute to a strong Buy recommendation for NewAmsterdam Pharma.
According to TipRanks, Ding is an analyst with an average return of -8.3% and a 37.70% success rate. Ding covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Amicus, and Rhythm Pharmaceuticals.